ClinicalTrials.gg
TerminatedNCT04248465Updated Jan 10, 2023Results posted

An Efficacy and Safety Study of Ravulizumab in ALS Participants

A Phase 3 interventional study of Placebo and Ravulizumab in Amyotrophic Lateral Sclerosis and ALS, sponsored by Alexion Pharmaceuticals, Inc.. Terminated at 95 sites in 17 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-01-10.

Sponsored by Alexion Pharmaceuticals, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Why this study was terminated
The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
382
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States — 98 open to participants now, 129 under way, 11 of them phase 3. Amyotrophic Lateral Sclerosis · United States.

Enrollment
21st of 307
382 · median 33
Started
2020
with 28 others
Phase 3
30 of 440
3 open now
Registered
256th of 440
by date

Among the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, this one is the 21st largest by enrollment of the 307 interventional ones that give a count, is one of 29 that started in 2020, is one of 30 in phase 3, and was the 256th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

98 of the 440 studies in Amyotrophic Lateral Sclerosis with a site in United States are open now. Recruiting first, the newest first:

93 more — sign in →

All 98 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 440 studies in Amyotrophic Lateral Sclerosis with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to assess the efficacy and safety of ravulizumab for the treatment of adult participants with ALS.

03

Conditions studied

  • Amyotrophic Lateral Sclerosis
  • ALS

Keywords

  • Ravulizumab
  • ALXN1210
  • Ultomiris
  • Motor Neuron Disease
  • Amyotrophic Lateral Sclerosis
  • ALS
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. A diagnosis of sporadic or familial ALS, defined by the El Escorial criteria (possible, laboratory-supported probable, probable, or definite ALS).
  2. ALS onset ≤ 36 months from Screening.
  3. Documented meningococcal vaccination not more than 3 years prior to, or at the time of, initiating study treatment.
  4. Upright slow vital capacity ≥ 65% predicted at Screening.
  5. If on riluzole, participant must be on a stable dose for 30 days; if on edaravone, participant must be on a stable dose for 60 days (2 cycles).
  6. Body weight ≥ 40 kilograms at Screening.
  7. use by men or women should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Key Exclusion Criteria:

  1. History of Neisseria meningitidis infection.
  2. (HIV) infection (evidenced by HIV 1 or HIV 2 antibody titer).
  3. Dependence on invasive or non-invasive mechanical ventilation.
  4. Previously or currently treated with a complement inhibitor.
  5. Exposure to an drug or device within 30 days of Screening or 5 half lives of the study drug, whichever is greater.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
382 participants (actual)

Study arms

  • Experimental
    Ravulizumab

    Participants will receive ravulizumab for the duration of the study.

    Biological: Ravulizumab

  • Placebo comparator
    Placebo

    Participants will receive placebo during the 50-week Randomized Controlled Period of the study, after which they will enter the Open-label Extension Period of the study and switch to receive ravulizumab.

    Drug: Placebo · Biological: Ravulizumab

Interventions

  • DrugPlacebo

    Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.

  • BiologicalRavulizumab

    Single loading dose via intravenous infusion, followed by regular maintenance dosing, based on weight.

    Also known as: ALXN1210, Ultomiris

06

What researchers measure

Primary outcomes

  1. Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score

    The ALSFRS-Revised is a validated instrument for evaluating the levels of the functional status of participants with amyotrophic lateral sclerosis (ALS) in 4 areas, including bulbar, gross motor activity, fine motor activity, and respiratory functions. The scale included 12 functional items and each item is rated on a 0 to 4 scale, with a maximum total score of 48. A higher score indicated greater retention of function. Baseline was defined as last non-missing value on or before first study drug administration.

    Time frame: Baseline, Week 50

Secondary outcomes

  1. Time To Ventilator Assistance-free Survival

    Ventilation Assistance-Free Survival (VAFS) is a composite endpoint of survival and severe and irreversible respiratory decline. The use of VAFS allowed for the collection of survival data that was not impacted by survival prolongation from noninvasive or permanent ventilatory interventions which could prolong life without impacting underlying disease progression.

    Time frame: Up to Week 50

  2. Change From Baseline In Percent Predicted Slow Vital Capacity

    Slow vital capacity measures slow and gradual expulsion of air from the lungs using a spirometer.

    Time frame: Baseline, Week 50

  3. Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, and TEAEs Leading To Study Drug Discontinuation

    An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

    Time frame: Baseline up to Week 156

  4. Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry

    Handheld dynamometry (HHD) is a procedure for quantitative strength testing. Muscle strength testing was performed on prespecified muscles in the upper and lower extremities bilaterally and the force measurements were recorded. Force of measurement is reported in megascores (lower, upper, total). The total megascore is defined as the average of the non-missing ratios over baseline for all the muscles involved. The megascore at baseline is always 100. The range of a potential megascore can not be determined in advance. A megascore \>100 indicates more strength compared to baseline.

    Time frame: Baseline, Week 50

  5. Change From Baseline In Serum Neurofilament Light Chain

    Time frame: Baseline, Week 50

  6. Change From Baseline in Serum Ravulizumab Concentration Over the Study Duration

    Time frame: Baseline, Predose at Week 50

  7. Change From Baseline in Serum Free Complement Component 5 (C5) Concentration Over the Study Duration

    Time frame: Baseline, Predose at Week 50

  8. Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210

    Blood samples were collected to evaluate antibody response through development of ADAs.

    Time frame: Week 50

07

Results

Posted Jan 10, 2023
Limitations and caveats
The IDMC recommended the study be discontinued due to lack of efficacy with ravulizumab.

Participant flow

Randomized-Controlled Period
Participant flow — Randomized-Controlled Period
MilestoneRavulizumab/RavulizumabPlacebo/Ravulizumab
Started255127
Received at least 1 dose of study drug255127
Completed155
Not completed240122
Withdrew: Death125
Withdrew: Adverse event20
Withdrew: Study terminated by sponsor19499
Withdrew: Withdrawal by subject3017
Withdrew: Physician decision11
Withdrew: Lost to follow-up10
Open-label Extension Period
Participant flow — Open-label Extension Period
MilestoneRavulizumab/RavulizumabPlacebo/Ravulizumab
Started145
Received at least 1 dose of study drug145
Completed00
Not completed145
Withdrew: Study terminated by sponsor144
Withdrew: Withdrawal by subject01

Outcome measures

PrimaryChange From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score

The ALSFRS-Revised is a validated instrument for evaluating the levels of the functional status of participants with amyotrophic lateral sclerosis (ALS) in 4 areas, including bulbar, gross motor activity, fine motor activity, and respiratory functions. The scale included 12 functional items and each item is rated on a 0 to 4 scale, with a maximum total score of 48. A higher score indicated greater retention of function. Baseline was defined as last non-missing value on or before first study drug administration.

Time frame:
Baseline, Week 50
Reported as:
Mean · units on a scale
Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score
units on a scaleRavulizumabPlacebo
Change From Baseline In Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised (ALSFRS-R) Total Score-11.9 ± 7.30-10.6 ± 6.05
SecondaryTime To Ventilator Assistance-free Survival

Ventilation Assistance-Free Survival (VAFS) is a composite endpoint of survival and severe and irreversible respiratory decline. The use of VAFS allowed for the collection of survival data that was not impacted by survival prolongation from noninvasive or permanent ventilatory interventions which could prolong life without impacting underlying disease progression.

Time frame:
Up to Week 50
Reported as:
Median · months
Time To Ventilator Assistance-free Survival
monthsRavulizumabPlacebo
Time To Ventilator Assistance-free Survival6.05 (0.79 to 11.10)7.69 (4.83 to 9.53)
SecondaryChange From Baseline In Percent Predicted Slow Vital Capacity

Slow vital capacity measures slow and gradual expulsion of air from the lungs using a spirometer.

Time frame:
Baseline, Week 50
Reported as:
Mean · percentage of predicted volume
Change From Baseline In Percent Predicted Slow Vital Capacity
percentage of predicted volumeRavulizumabPlacebo
Change From Baseline In Percent Predicted Slow Vital Capacity-20.9 ± 19.74-21.3 ± 13.90
SecondaryNumber of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, and TEAEs Leading To Study Drug Discontinuation

An adverse event (AE) was defined as any unfavorable and unintended sign (for example, including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or procedure, whether or not considered related to the medicinal product or procedure, which occurred during the course of the clinical study. TEAEs were defined as AEs that occurred on or after the date and time of study drug administration, or those that first occurred before dosing but worsened in frequency or severity after study drug administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Time frame:
Baseline up to Week 156
Reported as:
Count of participants · Participants
Number of Participants With Treatment-emergent Adverse Events (TEAEs), Treatment-emergent Serious Adverse Events, and TEAEs Leading To Study Drug Discontinuation
ParticipantsRavulizumabPlacebo
TEAEs204108
Treatment Emergent Serious AEs4124
TEAE Leading to Study Drug Discontinuation20
SecondaryChange From Baseline In Muscle Strength As Assessed By Handheld Dynamometry

Handheld dynamometry (HHD) is a procedure for quantitative strength testing. Muscle strength testing was performed on prespecified muscles in the upper and lower extremities bilaterally and the force measurements were recorded. Force of measurement is reported in megascores (lower, upper, total). The total megascore is defined as the average of the non-missing ratios over baseline for all the muscles involved. The megascore at baseline is always 100. The range of a potential megascore can not be determined in advance. A megascore \>100 indicates more strength compared to baseline.

Time frame:
Baseline, Week 50
Reported as:
Mean · % (as the unit of megascore)
Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry
% (as the unit of megascore)RavulizumabPlacebo
Change From Baseline In Muscle Strength As Assessed By Handheld Dynamometry-46.5 ± 27.57-53.4 ± 20.28
SecondaryChange From Baseline In Serum Neurofilament Light Chain
Time frame:
Baseline, Week 50
Reported as:
Mean · picograms/milliliter
Change From Baseline In Serum Neurofilament Light Chain
picograms/milliliterRavulizumabPlacebo
Change From Baseline In Serum Neurofilament Light Chain91.5 ± 40.4073.1 ± 27.82
SecondaryChange From Baseline in Serum Ravulizumab Concentration Over the Study Duration
Time frame:
Baseline, Predose at Week 50
Reported as:
Geometric mean · micrograms/milliliter
Change From Baseline in Serum Ravulizumab Concentration Over the Study Duration
micrograms/milliliterRavulizumab
Change From Baseline in Serum Ravulizumab Concentration Over the Study Duration634 ± 29.1
SecondaryChange From Baseline in Serum Free Complement Component 5 (C5) Concentration Over the Study Duration
Time frame:
Baseline, Predose at Week 50
Reported as:
Mean · micrograms/milliliter
Change From Baseline in Serum Free Complement Component 5 (C5) Concentration Over the Study Duration
micrograms/milliliterRavulizumabPlacebo
Change From Baseline in Serum Free Complement Component 5 (C5) Concentration Over the Study Duration-155.2 ± 24.42—
SecondaryNumber of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210

Blood samples were collected to evaluate antibody response through development of ADAs.

Time frame:
Week 50
Reported as:
Count of participants · Participants
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN1210
ParticipantsRavulizumabPlacebo
Number of Participants With Positive Antidrug Antibodies (ADAs) to ALXN12100—

Adverse events

Collected over Baseline up to Week 156. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Randomized Controlled Period: Ravulizumab15/255 (5.9%)41/255 (16.1%)196/255 (76.9%)
Randomized Controlled Period: Placebo6/127 (4.7%)24/127 (18.9%)106/127 (83.5%)
Open Label Extension Period: Ravulizumab0/14 (0%)2/14 (14.3%)3/14 (21.4%)
Open Label Extension Period: Placebo0/5 (0%)0/5 (0%)1/5 (20%)
Most frequent serious events
Showing 10 of 57
Most frequent serious events
EventRandomized Controlled Period: RavulizumabRandomized Controlled Period: PlaceboOpen Label Extension Period: RavulizumabOpen Label Extension Period: Placebo
COVID-19Infections and infestations0/2551/1271/140/5
CholecystitisHepatobiliary disorders0/2550/1271/140/5
PneumoniaInfections and infestations3/2555/1270/140/5
Respiratory failureRespiratory, thoracic and mediastinal disorders8/2554/1270/140/5
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2554/1270/140/5
DyspnoeaRespiratory, thoracic and mediastinal disorders3/2552/1270/140/5
Pneumonia aspirationInfections and infestations2/2552/1270/140/5
DysphagiaGastrointestinal disorders1/2552/1270/140/5
AspirationRespiratory, thoracic and mediastinal disorders0/2551/1270/140/5
CoughRespiratory, thoracic and mediastinal disorders0/2551/1270/140/5
Most frequent other events
Showing 10 of 15
Most frequent other events
EventRandomized Controlled Period: RavulizumabRandomized Controlled Period: PlaceboOpen Label Extension Period: RavulizumabOpen Label Extension Period: Placebo
FallInjury, poisoning and procedural complications54/25536/1271/141/5
HordeolumInfections and infestations0/2550/1270/141/5
Ankle fractureInjury, poisoning and procedural complications0/2550/1270/141/5
HeadacheNervous system disorders42/25522/1271/140/5
ConstipationGastrointestinal disorders26/2555/1270/140/5
NauseaGastrointestinal disorders23/25510/1270/140/5
FatigueGeneral disorders22/25511/1270/140/5
Urinary tract infectionInfections and infestations12/25511/1270/140/5
Back PainMusculoskeletal and connective tissue disorders21/2555/1270/140/5
Dermatitis contactSkin and subcutaneous tissue disorders0/2550/1271/140/5

Baseline characteristics

Full Analysis Set (FAS) included all randomized participants who received at least 1 dose of study drug grouped by randomized treatment group.

Age, Continuous
Age, Continuous(years)RavulizumabPlaceboTotal
Mean58.6 ± 10.5758.0 ± 11.0358.4 ± 10.72
Sex: Female, Male
Sex: Female, Male(Participants)RavulizumabPlaceboTotal
Female9458152
Male16169230
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RavulizumabPlaceboTotal
Hispanic or Latino221234
Not Hispanic or Latino205105310
Unknown or Not Reported281038
Race (NIH/OMB)
Race (NIH/OMB)(Participants)RavulizumabPlaceboTotal
American Indian or Alaska Native022
Asian221234
Native Hawaiian or Other Pacific Islander000
Black or African American101
White202103305
More than one race404
Unknown or Not Reported261036
08

Study locations

95 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Neuromuscular Research Center and Clinic
    Phoenix, Arizona 85028, United States
  • HonorHealth Research Institute
    Scottsdale, Arizona 85251, United States
  • Loma Linda University Medical Center
    Loma Linda, California 92354, United States
  • University of Southern California
    Los Angeles, California 90033, United States
  • University of California-Irvine
    Orange, California 92868, United States
  • Stanford University Medical Center
    Palo Alto, California 94304, United States
  • University of California San Diego Medical Center
    San Diego, California 92093-0949, United States
  • Norris MDA/ALS Center
    San Francisco, California 94115, United States
  • University of California San Francisco Medical Center
    San Francisco, California 94143, United States
  • University of Colorado Anschutz Medical Campus School of Medicine
    Aurora, Colorado 80045, United States
  • University of Florida at Shands Jacksonville
    Jacksonville, Florida 32209, United States
  • University of South Florida
    Tampa, Florida 33612, United States
  • University of Chicago Medical Center
    Chicago, Illinois 60637, United States
  • Indiana University Medical Center
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center Research Institute, Inc.
    Kansas City, Kansas 66160, United States
  • University of Kentucky
    Lexington, Kentucky 40536, United States
  • Johns Hopkins University School Of Medicine
    Baltimore, Maryland 21205, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Las Vegas Clinic
    Las Vegas, Nevada 89145, United States
  • Beth Israel Medical Center - PRIME
    New York, New York 10003, United States
  • Hospital for Special Surgery
    New York, New York 10021, United States
  • Atrium Health Neuroscience Institute
    Charlotte, North Carolina 28207, United States
  • The Cleveland Clinic Foundation
    Cleveland, Ohio 44195, United States
  • The Ohio State University
    Columbus, Ohio 43221, United States
  • Allegheny Neurological Associates
    Pittsburgh, Pennsylvania 15212, United States
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
  • Austin Neuromuscular Center
    Austin, Texas 78756, United States
  • Houston Methodist Neurological Institute-Movement Disorders Clinic
    Houston, Texas 77030, United States
  • Nerve & Muscle Center of Texas
    Houston, Texas 77030, United States
  • University of Vermont Medical Center
    Burlington, Vermont 05401, United States
  • Virginia Commonwealth University, Neurology Clinical and Translational Research Office
    Richmond, Virginia 23298, United States
  • Sentara Neurology Specialists
    Virginia Beach, Virginia 23456, United States
  • Swedish Neuroscience Institute
    Seattle, Washington 98122-4470, United States
  • Brain and Mind Centre
    Camperdown, New South Wales 2050, Australia
  • Westmead Hospital
    Westmead, New South Wales 2145, Australia
  • Royal Brisbane and Women's Hospital
    Herston, Queensland 4029, Australia
  • Perron Institute for Neurological and Translational Science
    Nedlands, Western Australia 6009, Australia
  • UZ Leuven
    Leuven, 3000, Belgium
  • Heritage Medical Research Centre (HMRC)
    Edmonton, Alberta T6G2S2, Canada
  • Stan Cassidy Center for Rehabilitation
    Fredericton, New Brunswick E3B 0C7, Canada
  • LHSC - University Hospital
    London, Ontario N6A 5A5, Canada
  • Toronto Sunnybrook Hospital
    Toronto, Ontario M4N 3M5, Canada
  • Montreal Neurological Institute and Hospital
    Montreal, Quebec H3A 2B4, Canada
  • University Hospital of Quebec-Universite Laval
    Québec, Quebec G1J 1Z4, Canada
  • Royal University Hospital
    Saskatoon, Saskatchewan S7K 0M7, Canada
  • Ålborg Universitets Hospital
    Aalborg, 9100, Denmark
  • Aarhus University Hospital Department of Neurology
    Aarhus, 8200, Denmark
  • Bispebjerg Hospital
    Copenhagen, 2400, Denmark
  • CHU de Nice Hôpital Pasteur 2
    Nice Cedex 1, Alpes Maritimes 06001, France
  • CHU de Limoges - Hôpital Dupuytren
    Limoges cedex, Haute Vienne 87042, France
  • Hopital Gui de Chauliac
    Montpellier, Herault 34295, France
  • CHU Tours - Hôpital Bretonneau
    Tours Cedex 9, Indre Et Loire 37044, France
  • Hopital Neurologique Pierre Wertheimer
    Bron cedex, Rhone 69677, France
  • Hopital Roger Salengro - CHU Lille
    Lille, 59037, France
  • Hôpital de la Timone
    Marseille, 13385, France
  • Groupe Hospitalier Pitie-Salpetriere
    Paris cedex 13, 75651, France
  • Universitaetsklinikum Ulm
    Ulm, Baden Wuerttemberg 89081, Germany
  • Klinikum rechts der Isar der TU Muenchen
    Muenchen, Bayern 81675, Germany
  • Universitaetsmedizin Goettingen
    Goettigen, Niedersachsen 37099, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Universitaetsklinikum Jena
    Jena, Thueringen 07749, Germany
  • Beaumont Hospital
    Dublin, DUBLIN 9, Ireland
  • Rambam Health Care Center
    Haifa, 91096, Israel
  • Hadassah University Hospital - Ein Kerem
    Jerusalem, 91120, Israel
  • Tel Aviv Sourasky Medical Center
    Tel Aviv, 6423906, Israel
  • Ospedale San Raffaele
    Milano, 20132, Italy
  • ICS Maugeri IRCCS
    Milano, 20138, Italy
  • Istituto Auxologico Italiano
    Milano, 20149, Italy
  • Azienda Ospedaliero-Universitaria di Modena - Ospedale Civile di Baggiovara
    Modena, 1355 - 41126, Italy
  • Azienda Ospedaliero Universitaria Policlinico Paolo Giaccone
    Palermo, 90127, Italy
  • Azienda Ospedaliero Universitaria Pisana
    Pisa, 56126, Italy
  • University of Turin
    Torino, 10126, Italy
  • Nagoya University Hospital
    Nagoya-shi, Aichi-Ken 466-8560, Japan
  • Chiba University Hospital
    Chiba-shi, Chiba-Ken 260-8677, Japan
  • Yoshino Neurology Clinic
    Ichikawa-shi, Chiba-Ken 272-0827, Japan
  • Tohoku University Hospital
    Sendai-shi, Miyagi-Ken 980-8574, Japan
  • Niigata University Medical & Dental Hospital
    Niigata-shi, Niigata-Ken 951-8520, Japan
  • Shiga University of Medical Science Hospital
    Ōtsu, Shiga-Ken 520-2192, Japan
  • Tokushima University Hospital
    Tokushima-shi, Tokushima-Ken 770-8503, Japan
  • Medical Hospital, Tokyo Medical and Dental University
    Bunkyo-ku, Tokyo-To 113-8519, Japan
  • Toho University Omori Medical Center
    Ota-ku, Tokyo-To 143-8541, Japan
  • Keio University Hospital
    Shinjuku-Ku, Tokyo-To 160-8582, Japan
  • University Medical Centre Utrecht
    Utrecht, 3508 GA, Netherlands
  • CityClinic
    Warszawa, 02-473, Poland
  • Hospital Universitari de Bellvitge
    L'Hospitalet De Llobregat, Barcelona 08907, Spain
  • Hospital de la Santa Creu i Sant Pau
    Barcelona, 08025, Spain
  • Hospital Universitari Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital San Rafael
    Madrid, 28016, Spain
  • Hospital Universitari i Politecnic La Fe
    Valencia, 46026, Spain
  • Karolinska Trial Alliance (KTA)
    Huddinge, 141 86, Sweden
  • Norrlands universitetssjukhus
    Umeå, 90185, Sweden
  • Kantonsspital St. Gallen
    Saint Gallen, 9007, Switzerland
  • The National Hospital for Neurology & Neurosurgery
    London, Greater London WC1N 3BG, United Kingdom
  • Royal Hallamshire Hospital
    Sheffield, West Midlands S10 2JF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2020 to primary completion in Oct 2021, 18 months.

Results were first posted in Jan 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2020
First posted
Jan 30, 2020
StartActual
Mar 30, 2020
Primary completionActual
Oct 17, 2021
CompletionActual
Oct 17, 2021
Results first posted
Jan 10, 2023
Last update
Jan 10, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 10, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04248465
Responsible party
Sponsor
First posted
Jan 30, 2020
Start date
Mar 30, 2020
Primary completion
Oct 17, 2021
Completion
Oct 17, 2021
Results posted
Jan 10, 2023
Last update
Jan 10, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ravulizumab

Start the discussion